Year: 2016
Type: review
Abstract: Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and health-economic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities in access to therapy based on economic differences across countries. Since approved biosimilars have already demonstrated highly similar efficacy, it will be most important to establish pharmacovigilance databases across countries that are adequate to monitor long-term safety after marketing approval.
Source: Annals of the Rheumatic Diseases
Institutions: German Rheumatism Research Centre, Charité – Universitätsmedizin Berlin, Stanford Medicine, Stanford University, University of Lisbon, Corvinus University of Budapest, University of Massachusetts Chan Medical School, UMass Memorial Medical Center, Diakonhjemmet Hospital, Klinik Hietzing, Medical University of Vienna, University of Occupational and Environmental Health Japan
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,870
Funder: F. Hoffmann-La Roche
OpenAlex ID: W2293590090